Research Discipline(s): Clinical, Translational, Health Services
Primary Title: Radiation Oncologist
Additional Titles & Affiliations: Associate Professor, Department of Radiology, Max Rady Faculty of Health Sciences, University of Manitoba
RESEARCH TOPICS
Lung Cancer, Prostate Cancer, Esophageal Cancer, Breast Cancer, Cancer Prevention, Early Detection, Cancer Epidemiology
Bringing tomorrow's cancer treatments to patients today through clinical trials
Research Summary
I am a clinician-scientist, Radiation Oncologist, and Associate Professor at CancerCare Manitoba/the University of Manitoba with clinical expertise in the care of prostate, lung, breast and esophageal cancer patients. My scientific research themes include: 1) Developing clinical trials designed to improve knowledge gaps of our current cancer treatments; 2) Collaborating with basic scientists to develop pre-clinical hypothesis-generating data for testing in phase I/II prospective clinical trials; 3) Developing knowledge translation interventions which bridge knowledge-to-action gaps in the everyday care of prostate/lung/breast/esophageal cancer patients.
Goals
- To improve the precision and cure rates of radiotherapy treatments for cancer
- To reduce the unwanted toxicities of current cancer treatments
- To translate research knowledge to clinical uptake and utilization
- To detect and treat cancers at the earliest stages
Research Biography
Dr. Kim’s research focuses on the development, operation and analysis of phase 2 and phase 3 investigator-initiated clinical trials in oncology geared towards improving cure rates, reducing treatment related toxicity, or detecting cancer early so that it can be managed better. He currently has prospective clinical trials in prostate, lung cancer, breast cancer and esophageal cancer which are testing interventions such as metformin in high-risk prostate cancer and high-precision real-time radiofrequency guidance techniques for stereotactic body radiotherapy of moving lung tumours. Dr. Kim has developed knowledge translation projects aimed at increasing the sustainable use of radiotherapy resources with the Canadian Partnership Against Cancer. Dr. Kim also has an interest in breast cancer risk assessment and prevention through lifestyle modification and the use of preventative medications.
Achievements
- Alberta Advanced Education Graduate Student Scholarship (2014)
- Michael J Hutchison Research Fellowship Award; Alberta Cancer Foundation (2012-2014)
-
Featured Publications
- Julian O. Kim*, Robert Balshaw, Connel Trevena, Shantanu Banerji, Leigh Murphy, David Dawe, Lawrence Tan, Sadeesh Srinathan, Gordon Buduhan, Biniam Kidane, Gefei Qing, Michael Domaratzki Michel Aliani. Data-driven identification of plasma metabolite clusters and metabolites of interest for potential detection of early-stage non-small cell lung cancer cases versus cancer-free controls. Cancer & Metabolism, Article-In-Press (2022) 10:16. DOI: https://doi.org/10.1186/s40170-022-00294-9
- Nawaid Usmani, Sunita Ghosh, Karan P Sanghera , Aldrich D Ong , Rashmi Koul, Arbind Dubey, Shahida Ahmed, Harvey Quon , Don Yee , Matthew Parliament , Gokulan Sivananthan, William Hunter, Brita Danielson, Lindsay Rowe, Megan McDonald, Julian O. Kim*. Metformin for Prevention of Anthropometric & Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial. International Journal of Radiation Oncology * Biology * Physics. Article-In-Press, Accepted 18 July 2022. DOI: https://doi.org/10.1016/j.ijrobp.2022.07.035
- Shaheer Shahhat, Nikesh Hanumanthappa, Youn Tae Chung, James Beck, Rashmi Koul, Bashir Bashir, Andrew Cooke, Arbind Dubey, Jim Butler, Maged Nashed, William Hunter, Aldrich D. Ong, Shrinivas Rathod, Kim Tran, Julian O. Kim*. Do sustainable palliative single fraction radiotherapy practices proliferate or perish 2 years after a knowledge translation campaign? Curr. Oncol. Vol 29 (7), 19 July 2022. DOI: https://doi.org/10.3390/curroncol29070404
- Julian O. Kim*, Megan O McDonald, Aldrich Ong, Rashmi Koul, Arbind Dubey, William Hunter, Shahida Ahmed, Harvey Quon, Don Yee, Matthew Parliament, Gokulan Sivananthan, Brita Danielson, Lindsay Rowe, Sunita Ghosh, Nawaid Usmani. Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: Interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial. Radiation Oncology. Vol 16 (1), 4 Nov 2021. DOI: 10.1186/s13014-021-01935-x
- Brett M. Hiebert, Bryan W. Janzen, Rohan M. Sanjanwala, Aldrich D. Ong, Ross D. Feldman, Julian O. Kim*. Impact of Spironolactone Exposure on Prostate Cancer Incidence Amongst Men with Heart Failure: A Pharmacoepidemiologic Study. British Journal of Clinical Pharmacology. Vol 87, March 2021, pages 1801-1813. DOI: 10.1111/bcp.14568
- Shaheer Shahhat, Nikesh Hanumanthappa, Youn Tae Chung, James Beck, Rashmi Koul, Bashir Bashir, Andrew Cooke, Arbind Dubey, Jim Butler, Maged Nashed, William Hunter, Shrinivas Rathod, Aldrich Ong, Kim Tran, Julian O. Kim*. Do Coordinated Knowledge Translation Campaigns Persuade Radiation Oncologists to Utilize Single Fraction Radiotherapy over Multiple Fraction Radiotherapy for Bone Metastases? International Journal of Radiation Oncology * Biology * Physics. Volume 109 (2), 1 Feb 2021, pages 365-373. https://doi.org/10.1016/j.ijrobp.2020.08.056
- Julian O. Kim, Daniel J. Schaid, Celine M. Vachon, Andrew Cooke, Fergus J. Couch, Christina A. Kim, Jason P. Sinnwell, Linda Hasadsri, Daniela L. Stan, Benjamin Goldenberg, Lonzetta Neal, Debjani Grenier, Amy C. Degnim, Lori A. Thicke, Sandhya Pruthi. Impact of Personalized Genetic Breast Cancer Risk Estimation with Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake. Cancer Prevention Research. Vol 14 (2), Feb 2021, Pages 175-184. https://doi.org/10.1158/1940-6207.capr-20-0154
- Biniam Kidane, Jonathan Spicer, Julian O. Kim, Pierre-Olivier Fiset, Bassam Abdulkarim, Richard A. Malthaner, David Palma. Stereotactic ABlative Radiotherapy Before Resection to avoId Delay for early-stage lunG cancer or oligomEts during the COVID-19 pandemic. Frontiers in Oncology, 10, 25 Sept 2020. https://doi.org/10.3389/fonc.2020.580189
